Heron Therapeutics (HRTX) Tops Q3 EPS by 1c

Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $32.81 million versus the consensus estimate of $36.61 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Pakistan's Sharif: Confirm That A Final, Agreed Text Reached